{"id":66742,"date":"2026-05-29T21:43:56","date_gmt":"2026-05-29T13:43:56","guid":{"rendered":"https:\/\/flcube.com\/?p=66742"},"modified":"2026-05-29T21:43:58","modified_gmt":"2026-05-29T13:43:58","slug":"sino-biopharmaceuticals-idh1-inhibitor-tqb3454-receives-nmpa-priority-review-for-biliary-tract-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66742","title":{"rendered":"Sino Biopharmaceutical&#8217;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/strong>, a subsidiary of <strong>Sino Biopharmaceutical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), announced that its <strong>Category 1 drug TQB3454<\/strong> has been granted <strong>priority review status<\/strong> by the <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>. The filing seeks approval for <strong>locally advanced, recurrent, and\/or metastatic biliary tract cancer (BTC)<\/strong> harboring <strong>IDH1 mutations<\/strong> in patients who have failed prior gemcitabine- and fluorouracil-based regimens.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-clinical-validation\" class=\"wp-block-heading\">Regulatory Milestone &amp; Clinical Validation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td><strong>Priority review<\/strong> awarded<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 1 (novel molecular entity)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>IDH1-mutated biliary tract cancer post-chemotherapy failure<\/td><\/tr><tr><td><strong>Clinical Validation<\/strong><\/td><td>Phase III study met primary endpoints at interim analysis (March 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-mechanism-amp-scientific-rationale\" class=\"wp-block-heading\">Drug Mechanism &amp; Scientific Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Mutant IDH1 enzymes specifically<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong><\/li>\n\n\n\n<li>Reduces downstream 2-hydroxyglutarate (2-HG) levels<\/li>\n\n\n\n<li>Reverses DNA and histone hypermethylation caused by elevated 2-HG<\/li>\n\n\n\n<li>Restores normal chromatin structure<\/li>\n\n\n\n<li>Promotes proper cellular differentiation and developmental processes<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Anti-malignant activity through epigenetic reprogramming of mutant cells<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pivotal-phase-iii-clinical-results\" class=\"wp-block-heading\">Pivotal Phase III Clinical Results<\/h2>\n\n\n\n<h3 id=\"h-tqb3454-iii-01-study-march-2026-interim-analysis\" class=\"wp-block-heading\">TQB3454-III-01 Study (March 2026 Interim Analysis)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression-Free Survival (PFS)<\/strong><\/td><td>Met protocol-prespecified superiority threshold<\/td><td>Statistically significant improvement<\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>Met protocol-prespecified superiority threshold<\/td><td>Clinically meaningful survival benefit<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>IDH1-mutated advanced biliary tract cancer<\/td><td>Genetically defined precision medicine approach<\/td><\/tr><tr><td><strong>Prior Therapy<\/strong><\/td><td>Failed gemcitabine- and fluorouracil-based regimens<\/td><td>Addresses high unmet need in refractory population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-therapeutic-context\" class=\"wp-block-heading\">Market Opportunity &amp; Therapeutic Context<\/h2>\n\n\n\n<h3 id=\"h-biliary-tract-cancer-landscape\" class=\"wp-block-heading\">Biliary Tract Cancer Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Incidence:<\/strong> Approximately 8,000-10,000 new BTC cases annually in China<\/li>\n\n\n\n<li><strong>IDH1 Mutation Prevalence:<\/strong> 10-20% of intrahepatic cholangiocarcinoma cases<\/li>\n\n\n\n<li><strong>Current Treatment Limitations:<\/strong> Limited effective options after first-line chemotherapy failure<\/li>\n\n\n\n<li><strong>Survival Outcomes:<\/strong> Median OS typically &lt;12 months in refractory setting<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-idh1-inhibitor-landscape\" class=\"wp-block-heading\">Competitive IDH1 Inhibitor Landscape<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Global Status<\/th><th>China Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Ivosidenib<\/strong><\/td><td>Servier\/Agios<\/td><td>Approved (U.S.\/EU)<\/td><td>Not approved<\/td><td>First-in-class but limited China access<\/td><\/tr><tr><td><strong>TQB3454<\/strong><\/td><td>Sino Biopharmaceutical\/CTTQ<\/td><td><strong>Phase III positive<\/strong><\/td><td><strong>NMPA priority review<\/strong><\/td><td><strong>Local development with potential pricing advantage<\/strong><\/td><\/tr><tr><td><strong>Other IDH1 Inhibitors<\/strong><\/td><td>Various<\/td><td>Early development<\/td><td>Preclinical<\/td><td>Limited late-stage data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-sino-biopharmaceutical-cttq\" class=\"wp-block-heading\">For Sino Biopharmaceutical\/CTTQ<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Medicine Leadership:<\/strong> Establishes position in genetically targeted oncology therapies<\/li>\n\n\n\n<li><strong>Commercial Advantage:<\/strong> Priority review accelerates time to market in underserved indication<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> Category 1 designation supports premium pricing in China<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Positive Phase III data could support international regulatory filings<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-oncology-market-dynamics\" class=\"wp-block-heading\">China Oncology Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Medicine Adoption:<\/strong> Increasing acceptance of biomarker-driven treatment approaches<\/li>\n\n\n\n<li><strong>Healthcare Policy Support:<\/strong> Government prioritizes domestic innovative drugs for rare mutations<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> Priority review often correlates with faster inclusion in national reimbursement drug list (NRDL)<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Need for increased IDH1 testing adoption in BTC clinical practice<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-commercial-outlook\" class=\"wp-block-heading\">Development Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Decision Expected:<\/strong> Q4 2026 &#8211; Q1 2027 (accelerated by priority review)<\/li>\n\n\n\n<li><strong>Market Launch:<\/strong> Anticipated H1 2027<\/li>\n\n\n\n<li><strong>Companion Diagnostic:<\/strong> Likely co-development with IDH1 mutation testing platforms<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Estimated \u00a5500-800 million annual peak sales in China BTC market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial potential for TQB3454. Actual results may differ due to risks including final NMPA approval decisions, market competition, companion diagnostic development, and evolving treatment guidelines for biliary tract cancer.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052800528_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052800528_c.\"><\/object><a id=\"wp-block-file--media-69f6e31f-50d0-4ea5-864e-8acdb3f73f9b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052800528_c.pdf\">2026052800528_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052800528_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-69f6e31f-50d0-4ea5-864e-8acdb3f73f9b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,661,908,80,313],"class_list":["post-66742","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-1177","tag-priority-reviews","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical&#039;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and\/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66742\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical&#039;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and\/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66742\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T13:43:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T13:43:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66742#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66742\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical&#8217;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer\",\"datePublished\":\"2026-05-29T13:43:56+00:00\",\"dateModified\":\"2026-05-29T13:43:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66742\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 1177\",\"Priority reviews\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66742#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66742\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66742\",\"name\":\"Sino Biopharmaceutical's IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T13:43:56+00:00\",\"dateModified\":\"2026-05-29T13:43:58+00:00\",\"description\":\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and\\\/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66742#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66742\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66742#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical&#8217;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical's IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and\/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66742","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical's IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer","og_description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and\/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.","og_url":"https:\/\/flcube.com\/?p=66742","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T13:43:56+00:00","article_modified_time":"2026-05-29T13:43:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66742#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66742"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical&#8217;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer","datePublished":"2026-05-29T13:43:56+00:00","dateModified":"2026-05-29T13:43:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66742"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Chia Tai Tianqing Pharmaceutical","HKG: 1177","Priority reviews","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66742#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66742","url":"https:\/\/flcube.com\/?p=66742","name":"Sino Biopharmaceutical's IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T13:43:56+00:00","dateModified":"2026-05-29T13:43:58+00:00","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and\/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66742#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66742"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66742#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical&#8217;s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66742"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66742\/revisions"}],"predecessor-version":[{"id":66747,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66742\/revisions\/66747"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}